医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Syngenta Receives China Import Approval for Agrisure Duracade® Corn Trait

2017年07月17日 PM10:00
このエントリーをはてなブックマークに追加


 

BASEL, Switzerland

Syngenta announced today that it has received notification of import approval from the Chinese Ministry of Agriculture for its Agrisure Duracade® trait. The approval covers corn grain and processing co-products, including dried distillers grains (DDGs), for food and feed use.

Erik Fyrwald, CEO, said: “Obtaining this regulatory approval opens up new opportunities for our corn seed portfolio. Growers can expect more choice and exciting new hybrids that offer elite genetics plus the latest in corn rootworm control technology.”

Corn rootworm costs US growers more than $1 billion annually due to yield losses and costs of control measures. Agrisure Duracade, which features a unique mode of action, helps deliver control of corn rootworm for a healthier corn crop with higher yield potential.

The Agrisure Duracade trait has completed the Food and Drug Administration consultation process, received registration from the Environmental Protection Agency and has been fully deregulated by the USDA since 2013.

About Syngenta

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 28,000 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit www.syngenta.com and www.goodgrowthplan.com. Follow us on Twitter® at www.twitter.com/Syngenta.

Cautionary statement regarding forward-looking statements

Some of the statements contained in this press release are forward-looking statements, which involves a number of risks and uncertainties discussed in Syngenta’s public filings with the SEC, including the “risk factors” section of Syngenta’s Form 20-F filed on February 16, 2017 as well as the U.S. Offer documents filed by ChemChina and CNAC Saturn (NL) B.V. (“Purchaser”) and the Solicitation/Recommendation Statement filed by Syngenta. These statements are based on current expectations, assumptions, estimates and projections, and involve known and unknown risks, uncertainties and other factors that may cause results, levels of activity, performance or achievements to be materially different from any forward-looking statements. These statements are generally identified by words or phrases such as “believe”, “anticipate”, “expect”, “intend”, “plan”, “will”, “may”, “should”, “estimate”, “predict”, “potential”, “continue” or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results and/or timing discussed in the forward-looking statements, and you should not place undue reliance on these statements. ChemChina, Purchaser and Syngenta disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this press release or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170717005503/en/

CONTACT

Syngenta International AG
Media Office
Tel: +41 61 323
2323
Fax: +41 61 323 2424
www.syngenta.com
or
Media
contacts:

Leandro Conti
Switzerland +41 61 323 2323
Paul
Minehart
USA +1 202 737 8913
media.relations@syngenta.com
or
Analyst/Investor
contacts:

Jennifer Gough
Switzerland +41 61 323 5059
USA
+1 202 737 6521

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者